

**S2 Table.** Summary of clinical trials in standard-risk medulloblastoma

Study	No.	Radiotherapy		Chemotherapy regimen	Total dose	Duration (wk)	Toxic death	Event-free survival	
		CSI (Gy)	Tumor bed (Gy)					5-yr	OS
SJMB96 <sup>a)</sup> [1]	86	23.4	55.8	4 Cycles of HDC (cisplatin, cyclophosphamide, and vincristine)	Cisplatin 300 mg/m <sup>2</sup> , vincristine 12 mg/m <sup>2</sup> , cyclophosphamide 16,000 mg/m <sup>2</sup>	16	0	5-yr EFS	83%
COGA99 61 [2]	379	23.4	55.8	Randomized 8 cycles of chemotherapy A or B (A: CCNU, cisplatin, vincristine, B: cisplatin, cyclophosphamide, vincristine)	Cisplatin 600 mg/m <sup>2</sup> , vincristine 36 mg/m <sup>2</sup> , and CCNU 600 mg/m <sup>2</sup> or cyclophosphamide 16,000 mg/m <sup>2</sup>	32	None reported	5-yr EFS	81% OS 87%
SJMB03 <sup>a)</sup> [3]	227	23.4	55.8	4 Cycles of HDC (cisplatin, cyclophosphamide, and vincristine)	Cisplatin 300 mg/m <sup>2</sup> , vincristine 8mg/m <sup>2</sup> , cyclophosphamide 16,000 mg/m <sup>2</sup>	16	17/330	5-yr EFS	83.2%
SIOP PNET-4 [4]	340	HFRT 36	60-68	8 Cycles of cisplatin, CCNU, and vincristine	Cisplatin 560 mg/m <sup>2</sup> , CCNU 600 mg/m <sup>2</sup> , vincristine 36 mg/m <sup>2</sup>	48	1	5-yr EFS	78% OS 85%
ACNS 0331 [5]	464	18 or 23.4	54	9 Cycles of chemotherapy (cisplatin, CCNU, vincristine and cyclophosphamide, vincristine)	Cisplatin 450 mg/m <sup>2</sup> , CCNU 450 mg/m <sup>2</sup> , cyclophosphamide 6,000 mg/m <sup>2</sup> , vincristine 36 mg/m <sup>2</sup>	48	None reported	5-yr EFS	81.4% OS 84.9%
KSPNO M051	24	23.4	55.8	8 Cycles of A course (cisplatin, vincristine, cyclophosphamide) and 4 cycles of B course (vincristine, cyclophosphamide)	Cisplatin 600 mg/m <sup>2</sup> , vincristine 54 mg/m <sup>2</sup> , cyclophosphamide 24,000 mg/m <sup>2</sup>	48	2	5-yr EFS	86.0% OS 95.7%

CCNU, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea; CSI, craniospinal irradiation; EFS, event-free survival; HDC, high-dose chemotherapy; OS, overall survival.

<sup>a)</sup>High-dose chemotherapy was attempted in this study.